Straits Times Index
3,365.67 -12.62 (-0.37%) S&P 500
4,017.77 -52.79 (-1.30%) Dow
33,717.09 -260.99 (-0.77%) Nasdaq
11,393.81 -227.90 (-1.96%) BTC-USD
22,945.56 -176.41 (-0.76%) CMC Crypto 200
520.61 -17.26 (-3.21%)
ABT Jan 2024 90.000 call
| Previous close | 28.06 |
| Open | 28.06 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 90.00 |
| Expiry date | 2024-01-19 |
| Day's range | 28.06 - 28.06 |
| Contract range | N/A |
| Volume | |
| Open interest | 139 |
- Motley Fool
Is Abbott Laboratories a Good Dividend Stock to Buy Now?
It's that time of year when Wall Street analysts start adjusting their predictions, and one dividend-paying stock, in particular, is getting a lot of positive attention. Abbott Laboratories (NYSE: ABT) reported fourth-quarter earnings on Thursday, Jan. 26. Since then, Sanford C. Bernstein, Raymond James, Stifel Nicolaus, and Barclays have all raised their price targets on the healthcare conglomerate.
- Zacks
Abbott (ABT) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- Motley Fool
Abbott's Sales and Earnings Are Sinking: Should Investors Worry?
Abbott (NYSE: ABT) reported its full-year and fourth-quarter results for 2022 on Wednesday. Abbott's bad news definitely jumped out. While Abbott's sales fell 12% on a reported basis, the year-over-year decline was only 6.1% excluding the impact of foreign exchange.
